Published in Thromb Res on March 15, 1997
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (2001) 3.64
Automated versus manual techniques for the prothrombin time test: results of proficiency assessment studies. Br J Haematol (1978) 3.50
Gastric fibrinolysis. A possible aetiological link with peptic ulcer. Lancet (1967) 3.47
The variability of measurements of the prothrombin time ratio in the National Quality Control Trials a follow-up study. Br J Haematol (1974) 3.42
Effects of low-dose oral contraceptives on blood coagulation. Br Med J (1968) 3.26
Survey of prothrombin time in National External Quality Assessment Scheme exercises (1980-87). J Clin Pathol (1988) 2.98
Progesterone oral contraception and blood coagulation. Br Med J (1969) 2.90
Effect of automation on prothrombin time test in NEQAS surveys. J Clin Pathol (1989) 2.84
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (1992) 2.76
Oral contraceptives, blood clotting and thrombosis. Br Med Bull (1978) 2.38
Managing oral anticoagulant therapy. Chest (2001) 2.25
Guidelines on preparation, certification, and use of certified plasmas for ISI calibration and INR determination. J Thromb Haemost (2004) 2.21
The correction of coagulometer effects on international normalized ratios: a multicentre evaluation. Br J Haematol (1994) 2.19
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (1998) 2.17
Dosage and control of oral anticoagulants: an international collaborative survey. Br J Haematol (1982) 2.14
Effects of "natural oestrogen" replacement therapy on menopausal symptoms and blood clotting. Br Med J (1975) 2.06
Effect of international sensitivity index (ISI) of thromboplastins on precision of international normalised ratios (INR) J Clin Pathol (1989) 1.93
Quality control trials of prothrombin time: an assessment of the performance in serial studies. J Clin Pathol (1979) 1.89
Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis. Br Med J (1978) 1.83
Coumarin therapy and platelet aggregation. Br Med J (1969) 1.75
The international normalized ratio. A guide to understanding and correcting its problems. Arch Intern Med (1994) 1.66
Platelet aggregation during oral contraception. Br Med J (1969) 1.63
Standardisation of oral anticoagulant treatment. Br Med J (Clin Res Ed) (1984) 1.60
Transsexualism: a legal perspective. J Med Ethics (1980) 1.60
Assessment of value of calibrated lyophilised plasmas to determine International Sensitivity Index for coagulometers. J Clin Pathol (1992) 1.59
The interpretation of prothrombin results: a national survey. Br J Haematol (1969) 1.59
Allergy to laboratory animals: a retrospective and a prospective study. Br J Ind Med (1983) 1.58
Resprouting as a key functional trait: how buds, protection and resources drive persistence after fire. New Phytol (2012) 1.58
Prevalence of malnutrition on admission to four hospitals in England. The Malnutrition Prevalence Group. Clin Nutr (2000) 1.56
Identification of a congenital defect of factor VII in a colony of beagle dogs: the clinical use of the plasma. J Clin Pathol (1971) 1.56
The British system for anticoagulant control. Thromb Diath Haemorrh (1975) 1.54
Validity of the British system for anticoagulant control using the national reagent. J Clin Pathol (1970) 1.54
Automation and prothrombin time: a United Kingdom field study of two widely used coagulometers. J Clin Pathol (1990) 1.49
Status of present and candidate international reference preparations (IRP) of thromboplastin for the prothrombin time. A report of the Subcommittee for Control of Anticoagulation. Thromb Haemost (1993) 1.45
Therapeutic ranges in anticoagulant administration. Br Med J (Clin Res Ed) (1985) 1.40
Coagulation studies as a prognostic index in acute liver failure. Br J Haematol (1975) 1.39
Abnormal fibrin polymerization in liver disease. Br J Haematol (1976) 1.39
Evidence for the release of gastric fibrinolytic activity into peripheral blood. Gut (1969) 1.34
Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. Br Med J (Clin Res Ed) (1987) 1.30
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest (1995) 1.24
Laboratory control of anticoagulant therapy. Semin Thromb Hemost (1986) 1.22
Effects of progestogen oral contraception with norethisterone on blood clotting and platelets. Br Med J (1972) 1.18
The bleeding time: current practice in the UK. Clin Lab Haematol (1984) 1.17
The system for laboratory control of oral anticoagulant therapy using the British comparative thromboplastin. J Med Lab Technol (1970) 1.17
Oestrogen-progestogen oral contraception and blood clotting: a long-term follow-up. Br Med J (1971) 1.16
Oral anticoagulants reassessed. Br Med J (Clin Res Ed) (1982) 1.13
The calibration of the second primary international reference preparation for thromboplastin (thromboplastin, human, plain, coded BCT/253). Thromb Haemost (1984) 1.12
Calibration of BCT/441, the ICSH reference preparation for thromboplastin. Thromb Haemost (1986) 1.12
Measuring partial thromboplastin-time. An international collaborative study. Lancet (1976) 1.12
An evaluation of APTT monitoring of low-dose heparin dosage in hip surgery. Thromb Haemost (1982) 1.11
An evaluation of chromogenic substrates in the control of oral anticoagulant therapy. Br J Haematol (1981) 1.10
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a rebuttal. J Thromb Haemost (2013) 1.10
A national standard for anticoagulant therapy. The Manchester comparative reagent. Lancet (1967) 1.10
The analysis of cThy28 expression in avian lymphocytes. Apoptosis (2001) 1.09
Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther (1998) 1.07
Cyanide intoxication in sheep: therapeutic value of oxygen or cobalt. Am J Vet Res (1977) 1.07
Anticoagulants in cardiac infarction. Lancet (1969) 1.07
Blood clotting and platelet aggregation during oral progestogen contraception: a follow-up study. Br Med J (1971) 1.07
Laboratory control of oral anticoagulants. Br Med J (Clin Res Ed) (1987) 1.06
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (1995) 1.05
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest (1992) 1.04
Survey of oral anticoagulant treatment in children. J Clin Pathol (1992) 1.02
Prostacyclin activity in amniotic fluid in pre-eclampsia. Lancet (1980) 1.02
Water-borne outbreak of viral gastroenteritis and Sonne dysentery. J Hyg (Lond) (1968) 1.02
Randomized study of adjusted versus fixed low dose heparin prophylaxis of deep vein thrombosis in hip surgery. Br J Surg (1989) 1.01
The partial thromboplastin (cephalin) time test. J Clin Pathol (1972) 1.00
A double-blind cross-over study of piperazine oestrone sulphate and placebo with coagulation studies. Br J Obstet Gynaecol (1980) 0.99
Pharmacotherapeutics of macrolides, lincomycins, and spectinomycin. J Am Vet Med Assoc (1980) 0.99
Effect of the choice of WHO International Reference Preparation for thromboplastin on International Normalised Ratios. J Clin Pathol (1993) 0.98
Effects of experimentally induced Pasteurella haemolytica pneumonia on the pharmacokinetics of erythromycin in the calf. Am J Vet Res (1985) 0.98
Comparison of prothrombin complex concentrate and vitamin K1 in oral anticoagulant reversal. Br Med J (1976) 0.97